Exicure (NASDAQ:XCUR – Get Free Report) and BioAtla (NASDAQ:BCAB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Insider & Institutional Ownership
42.8% of Exicure shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Exicure and BioAtla, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| BioAtla | 1 | 0 | 1 | 0 | 2.00 |
Earnings and Valuation
This table compares Exicure and BioAtla”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 14.15 | -$4.95 million | ($1.32) | -0.82 |
| BioAtla | $8.50 million | 0.26 | -$59.61 million | ($25.45) | -0.05 |
Exicure has higher earnings, but lower revenue than BioAtla. Exicure is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Exicure and BioAtla’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| BioAtla | N/A | N/A | -289.67% |
Risk & Volatility
Exicure has a beta of 3.64, indicating that its share price is 264% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Summary
BioAtla beats Exicure on 7 of the 13 factors compared between the two stocks.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
About BioAtla
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
